AR096628A1 - Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella - Google Patents

Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Info

Publication number
AR096628A1
AR096628A1 ARP140102285A ARP140102285A AR096628A1 AR 096628 A1 AR096628 A1 AR 096628A1 AR P140102285 A ARP140102285 A AR P140102285A AR P140102285 A ARP140102285 A AR P140102285A AR 096628 A1 AR096628 A1 AR 096628A1
Authority
AR
Argentina
Prior art keywords
cisteamine
pearls
delayed
formulation
methods
Prior art date
Application number
ARP140102285A
Other languages
English (en)
Inventor
Powell Kathlene
Muttavarapu Ramesh
Original Assignee
Raptor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52019418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR096628(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Raptor Pharmaceuticals Inc filed Critical Raptor Pharmaceuticals Inc
Publication of AR096628A1 publication Critical patent/AR096628A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Abstract

Forma de dosificación en perla recubierta entérica de cisteamina y métodos relacionados de fabricación y uso.
ARP140102285A 2013-06-17 2014-06-16 Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella AR096628A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361835965P 2013-06-17 2013-06-17

Publications (1)

Publication Number Publication Date
AR096628A1 true AR096628A1 (es) 2016-01-20

Family

ID=52019418

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102285A AR096628A1 (es) 2013-06-17 2014-06-16 Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Country Status (25)

Country Link
US (9) US9233077B2 (es)
EP (2) EP3939574A1 (es)
JP (1) JP6468661B2 (es)
KR (2) KR102281747B1 (es)
CN (2) CN105492000B (es)
AP (1) AP2015008925A0 (es)
AR (1) AR096628A1 (es)
AU (1) AU2014281702C1 (es)
BR (1) BR112015031417B1 (es)
CA (2) CA2914770C (es)
CL (1) CL2015003662A1 (es)
CU (1) CU20150178A7 (es)
EA (1) EA031255B8 (es)
HK (1) HK1218066A1 (es)
IL (2) IL302141A (es)
MX (1) MX2015017366A (es)
NI (1) NI201500177A (es)
NZ (1) NZ714517A (es)
PH (1) PH12015502783A1 (es)
SG (1) SG11201510126QA (es)
TN (1) TN2015000549A1 (es)
TW (1) TWI649100B (es)
UA (1) UA117833C2 (es)
WO (1) WO2014204881A1 (es)
ZA (1) ZA201508783B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
US10537528B2 (en) * 2015-11-16 2020-01-21 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (NASH) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
EP3308773A1 (en) * 2016-10-11 2018-04-18 Recordati Industria Chimica E Farmaceutica SPA Formulations of cysteamine and cysteamine derivatives
US11576871B2 (en) 2016-11-16 2023-02-14 The Regents Of The University Of California Formulations of cysteamine and cystamine
US10251850B2 (en) 2017-01-11 2019-04-09 Lupin Limited Process for preparation of cysteamine bitartrate
EA201992178A1 (ru) * 2017-03-15 2020-05-22 Сересин Инк. Фармацевтические композиции с высоким содержанием лекарственного средства из среднецепочечных триглицеридов и способы, связанные c ними
WO2023249087A1 (ja) * 2022-06-24 2023-12-28 三生医薬株式会社 医薬組成物およびその製造方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4110441A (en) 1974-04-29 1978-08-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Gamma-l-glutamyl cholamine phosphate
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4959306A (en) 1986-11-28 1990-09-25 Sclavo, Inc. Labeling design for a binding assay reagent
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5639743A (en) 1992-11-13 1997-06-17 University Of Georgia Research Foundation Compositions and methods for treating exocrine gland atrophy
CA2236344A1 (en) 1998-04-30 1999-10-30 Hemosol Inc. Hemoglobin-haptoglobin complexes
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
US6794414B1 (en) 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US20050004075A1 (en) 2000-12-13 2005-01-06 Walcom Animal Science (I.P.2) Limited Composition for regulating animal growth, method of manufacture and use thereof
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
GB2377874B (en) 2001-07-23 2005-06-22 Walcom Bio Chemicals Ind Ltd Poultry feed and the use thereof
US7449451B2 (en) 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
GB2379854B (en) 2001-09-19 2006-04-19 Walcom Animal Science Dairy cow feed and the use thereof
EP1461033B1 (en) 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
ES2497716T3 (es) 2002-01-04 2014-09-23 Sound Pharmaceuticals Incorporated Composiciones para utilizar en métodos destinados a tratar la pérdida auditiva
GB2386817B (en) 2002-02-20 2006-08-23 Walcom Animal Science Feed for fish and use therof
US8017651B2 (en) 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
GB2398497A (en) 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
US8029822B2 (en) 2003-05-22 2011-10-04 Osmotica Kereskedelmi és Seolgáltató KFT Rupturing controlled release device having a preformed passageway
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
JP4966665B2 (ja) 2003-11-19 2012-07-04 オメガ バイオ−ファーマ （アイ．ピー．１） リミテッド アルコール代謝を改善し、二日酔いの影響を軽減するための材料と方法
WO2005063226A1 (en) 2003-12-19 2005-07-14 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
WO2005092914A1 (en) 2004-03-22 2005-10-06 Blue Mountain Technology Development Lab Process for promoting proper folding of human serum albumin using a human serum albumin ligand
EP1744737A2 (en) 2004-05-03 2007-01-24 Omega Bio-Pharma (I.P.3) Limited Cysteamines for treating complications of hypercholesterolemia and diabetes
CN101111231A (zh) * 2005-03-29 2008-01-23 罗姆有限公司 包含具有影响调节物质递送的基质的小丸的多颗粒药用形式
CA2605631A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
US20070172514A1 (en) 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
PT1919458E (pt) 2006-01-27 2012-08-23 Univ California Cisteamina revestida entericamente, cisteamina e seus derivados
AR069500A1 (es) * 2007-11-30 2010-01-27 Univ California Metodos de tratamiento de la esteatohepatitis no alcoholica (nash ) utilizando productos de cisteamina
BRPI0907561A2 (pt) 2008-02-17 2015-08-04 Walcom Animal Science I P 3 Ltd Materiais e métodos para aperfeiçoamento da saúde de camarões
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US9730899B2 (en) * 2009-03-18 2017-08-15 Evonik Roehm Gmbh Controlled release pharmaceutical composition with resistance against the influence of ethanol employing a coating comprising neutral vinyl polymers and excipients
CN101653426A (zh) 2009-09-16 2010-02-24 冯利萍 一种高稳型半胱胺盐酸盐的缓释小丸及制备方法
CN101703472B (zh) * 2009-11-09 2011-06-22 上海邦成生物科技有限公司 一种半胱胺盐酸盐制粒包衣缓释产品及其制备方法
CN102077905B (zh) 2010-12-10 2013-01-02 无锡正大畜禽有限公司 一种肠溶盐酸半胱胺包膜颗粒的生产方法
US10463611B2 (en) * 2011-06-08 2019-11-05 Sti Pharma, Llc Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
SG10201800159QA (en) * 2011-11-22 2018-02-27 Univ California Cysteamine and/or cystamine for treating ischemic injury
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella

Also Published As

Publication number Publication date
AP2015008925A0 (en) 2015-12-31
WO2014204881A8 (en) 2016-02-18
US20160158170A1 (en) 2016-06-09
CA2914770C (en) 2016-09-27
KR102281747B1 (ko) 2021-07-26
US20150290139A1 (en) 2015-10-15
US20140370085A1 (en) 2014-12-18
CA2914770A1 (en) 2014-12-24
CA2938644A1 (en) 2014-12-24
AU2014281702A1 (en) 2015-12-10
CN110664780A (zh) 2020-01-10
KR102466253B1 (ko) 2022-11-10
EA031255B1 (ru) 2018-12-28
AU2014281702B2 (en) 2019-11-07
CA2938644C (en) 2019-08-27
US20160331704A1 (en) 2016-11-17
EA201690036A1 (ru) 2016-09-30
US20190298665A1 (en) 2019-10-03
UA117833C2 (uk) 2018-10-10
JP6468661B2 (ja) 2019-02-13
US11090279B2 (en) 2021-08-17
JP2016523250A (ja) 2016-08-08
MX2015017366A (es) 2016-07-13
TW201534357A (zh) 2015-09-16
SG11201510126QA (en) 2016-01-28
BR112015031417A8 (pt) 2021-06-22
TWI649100B (zh) 2019-02-01
EA031255B8 (ru) 2019-11-29
US20160095827A1 (en) 2016-04-07
PH12015502783A1 (en) 2016-03-21
CN105492000B (zh) 2019-11-15
US20170319513A1 (en) 2017-11-09
ZA201508783B (en) 2019-09-25
IL302141A (en) 2023-06-01
KR20160045053A (ko) 2016-04-26
EP3010491A1 (en) 2016-04-27
WO2014204881A1 (en) 2014-12-24
US9233077B2 (en) 2016-01-12
US20170319512A1 (en) 2017-11-09
NI201500177A (es) 2016-02-15
BR112015031417B1 (pt) 2022-12-27
TN2015000549A1 (en) 2017-04-06
BR112015031417A2 (pt) 2017-07-25
IL284823A (en) 2021-08-31
KR20210094140A (ko) 2021-07-28
CL2015003662A1 (es) 2016-08-05
CU20150178A7 (es) 2016-07-29
HK1218066A1 (zh) 2017-02-03
US20170319514A1 (en) 2017-11-09
NZ714517A (en) 2018-10-26
EP3010491A4 (en) 2016-05-18
AU2014281702C1 (en) 2020-05-14
CN110664780B (zh) 2022-09-27
EP3939574A1 (en) 2022-01-19
CN105492000A (zh) 2016-04-13
US9173851B1 (en) 2015-11-03

Similar Documents

Publication Publication Date Title
AR096628A1 (es) Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
IL263175B (en) Microbiota restoration therapy (mrt) compounds and methods of manufacture
EP3052476A4 (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
EP3054892A4 (en) Wax-based compositions, articles made therefrom, and methods of manufacture and use
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
EP2964142A4 (en) WAX BASE COMPOSITIONS, ITEMS PRODUCED THEREFROM, METHOD OF MANUFACTURE AND USE THEREOF
GB201301626D0 (en) Composition comprising 15-OHEPA and methods of using the same
EP3472260A4 (en) COMPOSITIONS AND METHODS FOR THE PRODUCTION AND USE OF ACIDIFICATING MATERIALS
GB2549433B (en) Aysmmetric composite memebranes and modified substrates used in their preparation
EP3534951A4 (en) ANTI-CD40 ANTIBODIES IN COMBINATION AND METHOD OF USES
EP3433035A4 (en) COMPOSITIONS AND METHODS OF USE IN SAND CASTING.
CL2016000231A1 (es) Preparados y formación de preparados usados en tecnología de concreto
PT3197466T (pt) Combinação de quinurenina e células apresentadoras de antígeno (apc) como agentes terapêuticos e métodos para seu uso na modulação imunológica
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
HK1214146A1 (zh) 益生精氨酸分解口服組合物以及製備和使用益生精氨酸分解口服組合物的方法
TWD179190S (zh) 肩包
FI20136136A (fi) Menetelmä kosmeettisten koostumusten valmistamiseksi, kosmeettiset koostumukset sekä niiden käyttö
GB201716923D0 (en) Area of use in tidal manipulation
GB201312375D0 (en) Microemulsion formulation and method of manufacture
PT3052476T (pt) Inibidores de nicotinimida substituídos de btk e sua preparação e uso no tratamento do cancro, inflamações e doenças autoimunes
TH1601002416A (th) องค์ประกอบสมุนไพร กระบวนการสำหรับการเตรียมองค์ประกอบสมุนไพร และการใช้องค์ประกอบสมุนไพรนั้น
CN302576561S (zh) 涂胶器
AU2013904774A0 (en) Methods and Preparation and Use of Xanthorrhoeaceae Compositions
AU2013901754A0 (en) Fabric care composition and method of use thereof

Legal Events

Date Code Title Description
FC Refusal